Brief: Ascletis Pharma Gets Positive Topline Results From Phase III Open-Label Study Of Denifanstat
29/01/2026 13:46
Jan 29 (Reuters) - Ascletis Pharma Inc 1672.HK: POSITIVE TOPLINE RESULTS FROM PHASE III OPEN-LABEL STUDY OF DENIFANSTAT (ASC40) Further company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026